BMJ | Relax! Data for 440,000 people in Asia: HPV vaccine safety report

Cervical cancer is one of the most common cancers in women 40 years.
2012 alone, there were 630,000 new cases of human papillomavirus (HPV)-related cancer, of which 530,000 (84%) were diagnosed with cervical cancer.
266,000 women with cervical cancer die from cancer, accounting for 8 per cent of cancer-related deaths among women worldwide.
more than 600,000 women worldwide will be newly diagnosed with cervical cancer by 2020, and more than 340,000 will be killed by cervical cancer, according to the latest figures from the World Health Organization's International Agency for Research on Cancer (IARC).
current World Health Organization recommendations for HPV immunization are priority vaccinations for girls aged 9-14 who have not had sex.
, 124 countries have incorporated HPV vaccination policies into their national immunization plans by 2019.
since June 2016, the Korea Centers for Disease Control and Prevention has also launched a two-dose program for two- or four-price HPV vaccines for adolescent girls ages 12-13.
in the first year of the program, the coverage of the first dose of HPV vaccine for women of appropriate age was 61.5 percent, and by 2018 it had increased to 87.2 percent.
although HPV vaccines are widely used worldwide, concerns about the safety of HPV vaccinations persist, and concerns about serious vaccine-related adverse events have undermined public confidence in immunization.
, a national queue study from South Korea assessed the link between HPV vaccination and adverse events among 440,000 Adolescent Girls in Asia, adding important evidence to the safety of HPV vaccines for Asian populations.
results were published in the latest issue of the British Medical Journal (BMJ).
researchers collected large-scale linked data through the Korea Immunization Registration Information System and the National Health Information Database between January 2017 and December 2019.
study covered 441,399 girls aged 11-14 who were vaccinated in 2017.
, 382,020 people were vaccinated against HPV and 59,379 were not vaccinated against HPV.
The main outcomes of the study were 33 serious adverse events, including endocrine (e.g. thyroid abnormalities, diabetes, etc.), gastrointestinal (Crohn's disease, ulcerative colitis, pancreatitis, peptic ulcers, etc.), cardiovascular (Reynolds syndrome, venous thromboembolism, vasculitis, hypertension, etc.), musculoskeletal, blood diseases, skin diseases and neurological diseases, etc.
results showed that no of the 33 pre-defined HPV vaccination-related adverse events were found during follow-up.
But compared to the non-vaccination group, the risk of migraines in the HPV vaccination group increased by 11% (incidence in both groups was 1235.0 / 100,000 - year vs 920.9 / 100,000 - year).
a second analysis using the self-controlled risk range confirmed that there was no direct association between HPV vaccination and severe adverse events, including migraines (adjusted HR-0.67, 95% confidence interval 0.58-0.78).
time, the results of different follow-up times (90 days, 180 days and 2 years) were consistent and stable with the results of different HPV vaccine subsypes.
In this regard, the researchers noted that hormonal changes and menstruation were common risk factors for migraines, and that girls vaccinated against HPV were more likely to have menstrual-related migraines, taking into account the difference in average age between the HPV vaccine group (12.42 years) and other vaccine groups (11.84 years), as well as the average age of Korean girls at the beginning of the season (12.7 years).
sensitivity analysis of these studies also supports the increased effect of age on migraines over time.
, consistent with previous studies in Europe and the United States, which further confirmed the safety of HPV in Asian populations.
: Yoon D, et al. Association between human papillomavirus vaccination and serious adverse events in South Korean adolescent girls: nationwide cohort study. Bmj. 2021 Jan 29; 372:m4931. doi: 10.1136/bmj.m4931.MedSci Original Source: MedSci Original Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Original" are owned by Mets Medical and are not authorized to reproduce, and any media, website or individual may not reproduce them with the words "Source: Met Medical".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here